Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Taro ElixSure “Spill-Resistant” Cough/Cold Medicines For Children Debut

This article was originally published in The Tan Sheet

Executive Summary

Taro Consumer Healthcare Products will back its new ElixSure line of cough/cold medicines for children with $22 mil. in promotional spending through 2004

Taro Consumer Healthcare Products will back its new ElixSure line of cough/cold medicines for children with $22 mil. in promotional spending through 2004.

Support for the "unique patented spill resistant syrup" will include $10 mil. in print, television and media ads, with 15 TV spots slated to air during the cough/cold season in addition to ads in women's and parenting magazines such as Redbook, People and Parents.

Taro also plans to drop two full-page $1-off FSIs in October and January. Other promotional activities will include "eye-popping" floor displays, sampling and detailing to pediatricians, the company said.

The generics firm announced the launch of five ElixSure products at the National Association of Chain Drug Stores Marketplace in San Diego June 8-10.

The drugs feature Taro's NonSpil liquid drug delivery system, which the firm noted "pours like a liquid but resists spilling." Taro submitted an NDA for the tech-nology in 2002 and holds several patents for the system.

In promotional materials, Taro notes "the administration of liquid medicines to children is often a source of frustration for parents, physicians and children" that can lead to "spills, stains and in some cases, a question of the accuracy of the dose." ElixSure "assures dose goes from spoon to mouth without spilling," Taro said.

The products also allow children to receive "only the symptom relief [they] need as each formula has only one active ingredient to treat one symptom," materials state.

ElixSure Fever/Pain formula with acetaminophen "relieves sore throat pain" and will be available in cherry, grape and bubble gum flavors. The "non-drowsy" cough formula with dextromethorphan will come in cherry bubble gum flavor, while ElixSure Congestion with pseudoephedrine to "relieve stuffy nose & sinus pressure" will be offered in grape bubble gum flavor.

The cough and congestion formulas are indicated for children 10 and under, while the fever/pain offering is recommended for kids 12 and under. ElixSure formulas will cost $5.99 per 4 fl. oz. bottle, Taro noted.

At the end of 2002, Taro reorganized its U.S. operations into three divisions - Taro Generics, TaroPharma and Taro Consumer Healthcare Products. The consumer healthcare unit "was formed to market proprietary OTC products directly to consumers," Taro explained.

Related Content

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS095618

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel